Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Thursday, February 27th, 2025

Navigating Challenges and Innovations: CSPC Innovation Pharmaceutical Co’s Strategic Transformation and Growth Prospects

Date of Report

25 October 2024

Broker Name

UOB Kay Hian

Company Overview

CSPC Innovation Pharmaceutical Co is a producer of functional raw materials and health food that is transforming itself into a leading drug innovator in China.

Stock Data

  • Share Price: Rmb31.13
  • Target Price: Rmb37.00
  • Upside: +18.9%
  • Bloomberg Ticker: 300765 CH
  • Shares Issued: 1,404.6 million
  • Market Cap: Rmb43,725.0 million (US$6,141.6 million)
  • 3-Month Average Daily Turnover: US$38.3 million
  • 52-Week High/Low: Rmb40.62/Rmb18.82

Financial Performance

9M24 Results

  • Revenue: Rmb1,479 million (down 23.7% YoY)
  • Adjusted Net Earnings: Rmb137 million (down 76.3% YoY)
  • Net Profit: Rmb139 million (down 63.5% YoY)

Key Financials

Year Net Turnover (Rmbm) EBITDA (Rmbm) Net Profit (rep.) (Rmbm) Net Profit (adj.) (Rmbm)
2022 2,626 1,155 726 658
2023 2,502 869 756 744
2024F 1,988 53 146 146
2025F 3,176 537 508 508
2026F 3,990 993 902 902

Key Financial Metrics

  • FY24 NAV/Share: Rmb2.50
  • FY24 Net Cash/Share: Rmb1.00
  • PE Ratio (2024F): 369.6x
  • Dividend Yield: 0.0%

Stock Impact

  • Revenue Decline: 3Q24 revenue declined 14.5% YoY, largely due to a significant decrease in the average selling price (ASP) of caffeine raw materials, impacting revenue from the health food segment due to weak market demand.
  • R&D Investment: R&D expenses increased by 49.9% YoY to Rmb205 million in 3Q24, raising the R&D expense/revenue ratio from 22.5% in 9M23 to 30.9% in 9M24.

Product Launches and Innovations

  • New Biopharmaceutical Products: CSPC Innovation launched the Enlonstobart injection (PD-1 mAb) in June 2024 and received market approval for its Omalizumab biosimilar in October 2024. The company aims to generate substantial revenue from these products.

Acquisition of CSPC Baike

  • Acquisition Details: CSPC Innovation is on track to acquire a 100% stake in CSPC Baike for Rmb7.6 billion, which includes both share and cash consideration.
  • Expected Profit Contribution: CSPC Baike has guaranteed a minimum net profit of Rmb435 million for 2024.

Risks and Earnings Revision

  • Earnings Forecast: The 2024 revenue and adjusted net earnings growth estimates have been revised to -20.5% and -80.4% YoY, respectively.
  • Key Risks: Include policy risks, intensifying competition, R&D risks, and potential failures in M&A activities.

Valuation and Recommendation

  • Recommendation: Maintain BUY with a target price of Rmb37.00, based on a DCF model assuming a WACC of 10.2% and terminal growth rate of 3%.

Stock Price Catalysts

  • Successful acquisition of CSPC Baike and continued efforts in R&D and innovative drug launches are seen as key catalysts for growth.

Dyna-Mac Delisting: Shareholders Exit as Company Faces Uncertain Future Post-M&A Shake-Up

The delisting of Singapore-based offshore oil and gas contractor Dyna-Mac, following its acquisition by South Korea’s Hanwha Group, has sparked debate about the company’s future and the implications for shareholders. While some investors might...

Axiata’s Strategic Merger: XL Axiata and Smartfren Join Forces to Create Indonesia’s 3rd Largest Telco

Axiata Group Berhad: Strategic Merger and Market Insights Axiata Group Berhad: Strategic Merger and Market Insights Date of Report: Thursday, 12 December 2024 Broker Name: UOB Kay Hian Introduction to Axiata Group Berhad Axiata...

iFAST Corporation Achieves Record Growth with Strong 3Q24 Performance and Rising AUA

Date of Report: October 29, 2024Broker: UOB Kay Hian Private Limited Company Overview iFAST Corporation (iFAST) is a fintech wealth management platform based in Singapore, providing a broad range of investment products and services...